Beiträge | Year in Review 2022

Mammakarzinom HR+ Year in Review

Year in Review 2022

M.Banys-Paluchowski, M. Untch, H. Tesch, F.-A. Taran, F. Schütz

EBC - Endokrine Response / CDK4/6i Benefit / PARPi...

ADAPT; Cycle monarchE

Year in Review

F. Schütz, M. Untch, M. Banys-Paluchowski, H. Tesch, F.-A. Taran

MBC Unterschiede: CDK4/6i & SERDs; Update: ADC &...

MONARCH 3; PALOMA-2; RIGHT Choice; EMERALD; AMEERA; acelERA BC; TROPICS-02; DESTINY-Breast04

Year in Review 2022

D. Krug, C. Thomssen

Hypofraktionierung / RT LAW / SLNE oder TAD

Alliance; OMA; POLAR

Mammakarzinom HER2+ Year in Review

Year in Review 2022

T. Fehm, R. Bartsch, M. Thill

EBC Adjuvant / Neoadjuvant / Immuntherapie

APHINITY; KAITLIN; PerELISA; ADAPT; IMpassion050

Year in Review 2022

B. Aktas, A. Hartkopf, V. Müller

MBC ADC / Triplepositives MBC / Hirnmetastasen

DESTINY-Breast02; DESTINY-Breast03; DETECT V; HER2CLIMB; TUXEDO-1

Year in Review 2022

D. Krug, C. Thomssen

Hypofraktionierung / RT LAW / SLNE oder TAD

Alliance; OMA; POLAR

Mammakarzinom TNBC Year in Review

Year in Review 2022

C. Kolberg-Liedtke, J. Ettl, M. Welslau

MBC – Immuntherapie, CPS / ADC

DESTINY-Breast04; KEYNOTE-355

Year in Review 2022

I. Witzel, H.-C. Kolberg, E. Stickeler

EBC – Immuntherapie /Carboplatin?/PARPi

KEYNOTE-522; NeoMono; NACT; OlympiA

Year in Review 2022

D. Krug, C. Thomssen

Hypofraktionierung / RT LAW / SLNE oder TAD

Alliance; OMA; POLAR

GI Tumoren Year in Review

Year in Review 2022

A. Vogel, J. Trojan, S. Lorenzen, D. Arnold, D. Modest, A. Reinacher-Schick

Year in Review: HCC und BTC

Year in Review 2022

S. Lorenzen, D. Arnold, A. Vogel, J. Trojan, A. Reinacher-Schick, D. Modest

Year in Review: Upper GI

Year in Review 2022

D. Arnold, A. Vogel, D. Modest, J. Trojan, S. Lorenzen, A. Reinacher-Schick

Year in Review: Pankreas-Ca

Year in Review 2022

D. Modest, A. Reinacher-Schick, D. Arnold, A. Vogel, J. Trojan, S. Lorenzen

Year in Review: CRC

Präzisionsonkologie Year in Review

Year in Review 2022

A. Quaas, M. Thomas, D. Arnold

Year in Review: Präzisionsonkologie